Greetings, and drop me a line

To the readers of FierceBiotechResearch, I hope your holidays were restful, and you're now geared up for 2012.

And while we're ramping up for 2012, I also wanted to formally introduce myself.

I have written about life sciences and biotechnology research for about a decade out of my 19-year journalism/media career.

For a brief chunk of that time, I crossed over to "the other side," and handled life sciences media relations for an Ivy League university. While there, my mission was to seek out cutting-edge research aimed at better understanding genetic triggers for disease, as well as discoveries that could lead to new drugs for treating all kinds of illnesses.

And now at FBR, my mission is to find those stories for you, our readers.

Let me know what you think. Feel free to email or tweet your comments or suggestions, and if you hear about something amazing in the biotech research world, I'm all ears. (twitter | email)

Suggested Articles

Compass' CD137 agonist cleared large tumors in mice that other I-O agents had failed to treat. It's advancing the drug into phase 1 human trials.

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.